STAT3-EphA7 axis contributes to the progression of esophageal squamous cell carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Chen J, Kwong DL, Cao T, et al. Esophageal squamous cell carcinoma (ESCC): advance in genomics and molecular genetics. Dis Esophagus. 2015;28(1):84–89. doi: 10.1111/dote.12088.
   PubMed Web of Science ®Google Scholar
• Eyre R, Alferez DG, Santiago-Gomez A, et al. Microenvironmental IL1beta promotes breast cancer metastatic colonisation in the bone via activation of wnt signalling. Nat Commun. 2019;10(1):5016. doi: 10.1038/s41467-019-12807-0.
   PubMed Web of Science ®Google Scholar
• Frohlich J, Mazza T, Sobolewski C, et al. GDF11 rapidly increases lipid accumulation in liver cancer cells through ALK5-dependent signaling. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(6):158920. doi: 10.1016/j.bbalip.2021.158920.
   PubMed Web of Science ®Google Scholar
• Kuo CN, Pan JJ, Huang YW, et al. Association between nonsteroidal anti-inflammatory drugs and colorectal cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2018;27(7):737–745. doi: 10.1158/1055-9965.EPI-17-0876.
   PubMed Web of Science ®Google Scholar
• Tulotta C, Lefley DV, Freeman K, et al. Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment. Clin Cancer Res. 2019;25(9):2769–2782. doi: 10.1158/1078-0432.CCR-18-2202.
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–1134. doi: 10.1016/j.cell.2010.06.011.
   PubMed Web of Science ®Google Scholar
• McDonell LM, Kernohan KD, Boycott KM, et al. Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin. Hum Mol Genet. 2015;24(R1):R60–66. doi: 10.1093/hmg/ddv254.
   PubMed Web of Science ®Google Scholar
• Taylor H, Campbell J, Nobes CD. Ephs and ephrins. Curr Biol. 2017;27(3):R90–R95. doi: 10.1016/j.cub.2017.01.003.
   PubMed Web of Science ®Google Scholar
• Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008;133(1):38–52. doi: 10.1016/j.cell.2008.03.011.
   PubMed Web of Science ®Google Scholar
• Taneja R, Thisse B, Rijli FM, et al. The expression pattern of the mouse receptor tyrosine kinase GeneMDK1Is conserved through evolution and requires Hoxa-2for rhombomere-specific expression in mouse embryos. Dev Biol. 1996;177(2):397–412. doi: 10.1006/dbio.1996.0173.
   PubMed Web of Science ®Google Scholar
• Erturk E, Tuna G, Coskun D, et al. Investigation of anti-Cancer activity of newly synthesized 2,4-pentadien-1-one derivative containing benzofuran in human lung and colon cancer cells. Eurasian J Med Oncol. 2023;7(1):24–33. doi: 10.14744/ejmo.2023.61594.
   Google Scholar
• Li R, Sun Y, Jiang A, et al. Knockdown of ephrin receptor A7 suppresses the proliferation and metastasis of A549 human lung cancer cells. Mol Med Rep. 2016;13(4):3190–3196. doi: 10.3892/mmr.2016.4904.
   PubMed Web of Science ®Google Scholar
• Tu Y, Cai Q, Zhu X, et al. Down-regulation of HCP5 inhibits cell proliferation, migration, and invasion through regulating EPHA7 by competitively binding miR-101 in osteosarcoma. Braz J Med Biol Res. 2021;54(2):e9161. doi: 10.1590/1414-431X20209161.
   PubMed Web of Science ®Google Scholar
• Di W, Weinan X, Xin L, et al. Long noncoding RNA SNHG14 facilitates colorectal cancer metastasis through targeting EZH2-regulated EPHA7. Cell Death Dis. 2019;10(7):514. doi: 10.1038/s41419-019-1707-x.
   PubMed Web of Science ®Google Scholar
• Li S, Wu Z, Ma P, et al. Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression. Cell Death Dis. 2017;8(10):e3122–e3122. doi: 10.1038/cddis.2017.507.
   PubMed Web of Science ®Google Scholar
• Oricchio E, Wendel HG. Mining the cancer genome uncovers therapeutic activity of EphA7 against lymphoma. Cell Cycle. 2012;11(6):1076–1080. doi: 10.4161/cc.11.6.19451.
   PubMed Web of Science ®Google Scholar
• Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16(1):293–322. doi: 10.1146/annurev.immunol.16.1.293.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161–170. doi: 10.1056/NEJMra1202117.
   PubMed Web of Science ®Google Scholar
• Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene. 2000;19(21):2474–2488. doi: 10.1038/sj.onc.1203527.
   PubMed Web of Science ®Google Scholar
• Carpenter RL, Lo HW. STAT3 target genes relevant to human cancers. Cancers (Basel). 2014;6(2):897–925. doi: 10.3390/cancers6020897.
   PubMed Web of Science ®Google Scholar
• Tian F, Yang X, Liu Y, et al. Constitutive activated STAT3 is an essential regulator and therapeutic target in esophageal squamous cell carcinoma. Oncotarget. 2017;8(51):88719–88729. doi: 10.18632/oncotarget.20838.
   PubMedGoogle Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi: 10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Chen L, Bi S, Hou J, et al. Targeting p21-activated kinase 1 inhibits growth and metastasis via Raf1/MEK1/ERK signaling in esophageal squamous cell carcinoma cells. Cell Commun Signal. 2019;17(1):31. doi: 10.1186/s12964-019-0343-5.
   PubMed Web of Science ®Google Scholar
• Cheng X, Wei L, Huang X, et al. Solute carrier family 39 member 6 gene promotes aggressiveness of esophageal carcinoma cells by increasing intracellular levels of zinc, activating phosphatidylinositol 3-Kinase signaling, and up-regulating genes that regulate metastasis. Gastroenterology. 2017;152(8):1985–1997.e12. doi: 10.1053/j.gastro.2017.02.006.
   PubMed Web of Science ®Google Scholar
• Lin DC, Hao JJ, Nagata Y, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet. 2014;46(5):467–473. doi: 10.1038/ng.2935.
   PubMed Web of Science ®Google Scholar
• Adams RH, Klein R. Eph receptors and ephrin ligands. Essential mediators of vascular development. Trends Cardiovasc Med. 2000;10(5):183–188. doi: 10.1016/s1050-1738(00)00046-3.
   PubMed Web of Science ®Google Scholar
• Genander M, Frisen J. Ephrins and eph receptors in stem cells and cancer. Curr Opin Cell Biol. 2010;22(5):611–616. doi: 10.1016/j.ceb.2010.08.005.
   PubMed Web of Science ®Google Scholar
• Kou CJ, Kandpal RP. Differential expression patterns of EPH receptors and ephrin ligands in human cancers. Biomed Res Int. 2018;2018:7390104–7390123. doi: 10.1155/2018/7390104.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Kato H, Fukuchi M, et al. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer. 2003;103(5):657–663. doi: 10.1002/ijc.10860.
   PubMed Web of Science ®Google Scholar
• Chen X, Lu B, Ma Q, et al. EphA3 inhibits migration and invasion of esophageal cancer cells by activating the mesenchymalepithelial transition process. Int J Oncol. 2019;54(2):722–732. doi: 10.3892/ijo.2018.4639.
   PubMed Web of Science ®Google Scholar
• Zhang R, Liu J, Zhang W, et al. EphA5 knockdown enhances the invasion and migration ability of esophageal squamous cell carcinoma via epithelial-mesenchymal transition through activating WNT/beta-catenin pathway. Cancer Cell Int. 2020;20(1):20. doi: 10.1186/s12935-020-1101-x.
   PubMed Web of Science ®Google Scholar
• Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther. 2006;6(3):231–241. doi: 10.1517/14712598.6.3.231.
   PubMed Web of Science ®Google Scholar
• Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736–746. doi: 10.1038/nrc3818.
   PubMed Web of Science ®Google Scholar
• Yoon S, Choi JH, Kim SJ, et al. EPHB6 mutation induces cell adhesion-mediated paclitaxel resistance via EPHA2 and CDH11 expression. Exp Mol Med. 2019;51(6):1–12. doi: 10.1038/s12276-019-0261-z.
   Web of Science ®Google Scholar